Way Towards New Life

Neurological Disorders Medications

Alleviare promptly facilitates Indian patients and physicians under Named Patient Programs (NPP) to access imported authorized medicines that are not locally available to them.

Get access to an unapproved drug for personal use.

Here is a list of some of the Anti-Cancer Drugs for Neurological Disorders for which we currently have a NPP in place. If you are a patient or  healthcare professional, please click below on each to access details and information.

EVRYSDI (risdiplam) for oral solution

EVRYSDI is a prescription medicine used for the treatment of spinal muscular atrophy (SMA).

FABRAZYME (agalsidase beta) for injection

FABRAZYME is a prescription drug that’s used to treat a certain inherited disorder (Fabry disease)

KESIMPTA (ofatumumab) injection

KESIMPTA is a prescription medicine used for the treatment of relapsing forms of multiple sclerosis (MS),.

LOKELMA (sodium zirconium cyclosilicate)

LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults

RELYVRIO (sodium phenylbutyrate and taurursodiol)

RELYVRIO is a prescription medicine used for the treatment of amyotrophic lateral sclerosis (ALS) in adults.

RXULTI (brexpiprazole) tablet

RXULTI is indicated for the treatment of schizophrenia in adults. Brand Name: RXULTI 0.25 mg film-coated tablet

TAKHZYRO (lanadelumab) for injection

TAKHZYRO is a prescriptio medicine used in adults, and adolescents aged 12 years and older to prevent

UNITUXIN (dinutuximab) injection

For the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

Query Form

We would love to speak with you.
Feel free to reach out using the below details.

Access Unauthorized Medicines In India Under NPP.

What is Named-patient access programme (NPP)?

Named-patient basis access can also refer to a medicine for a specific patient or patients that is not (yet) authorised and available to them in their own country. Such medicine should or must (depending on legislation) be authorised in at least one country, from which it can be imported into the patient’s country under a Named-patient access programme (NPP).

These may be medicines that are:

  • Authorised but not yet available to be prescribed in the patient’s country.
  • Authorised and available in one country but not authorised and available in the patient’s country.
  • Discontinued in the patient’s country but not in another country.
  • In shortage in the patient’s country but not in another country.

Antibiotic

Arthritis

Diabetes

Genetics

Disorders

Hepatitis C

Hematologic Cancers

HIV/AIDS

Immunological Disorders

Liver Disease

Multiple Sclerosis

Nerver Disease

Oncology

Parkinson's Disease

Rare Disease

Soft Tissue Sarcoma

Transplant

Specialty Drugs

Get Access to an Unapproved Drug

For personal use, get access to an imported medicines (unapproved drug in India) for Neurological Disorders. On request, Anti-cancer medicines can be imported to following cities in India – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Alleviare provides only information & in any way, does not lay any claim on these brand names &/or trademarks.